Search

Your search keyword '"Song, Young Shin"' showing total 183 results
Start Over Author "Song, Young Shin"
183 results on '"Song, Young Shin"'

4. Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024

Author

Park, Young Joo, primary, Lee, Eun Kyung, additional, Song, Young Shin, additional, Kang, Su Hwan, additional, Koo, Bon Seok, additional, Kim, Sun Wook, additional, Na, Dong Gyu, additional, Baek, Seung-Kuk, additional, Oh, So Won, additional, Lee, Min Kyoung, additional, Lee, Sang-Woo, additional, Lee, Young Ah, additional, Lee, Yong Sang, additional, Lee, Ji Ye, additional, Lim, Dong-Jun, additional, Joo, Leehi, additional, Jung, Yuh-Seog, additional, Jung, Chan Kwon, additional, Cho, Yoon Young, additional, Chung, Yun Jae, additional, Kim, Won Bae, additional, Yi, Ka Hee, additional, Kang, Ho-Cheol, additional, and Park, Do Joon, additional

Published
2024
Full Text
View/download PDF

13. Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.

Author

Song, Young Shin, Yang, Hannah, Kang, Beodeul, Cheon, Jaekyung, Kim, Ilhwan, Kim, Hyeyeong, Lee, Won Suk, Sang, Yun Beom, Jung, Sanghoon, Lim, Ho Yeong, Gaillard, Vincent E., Kim, Chan, and Chon, Hong Jae

Subjects
ATEZOLIZUMAB, HEPATOCELLULAR carcinoma, BEVACIZUMAB, IMMUNE checkpoint inhibitors, THYROID cancer, TREATMENT effectiveness, THYROID diseases
Abstract

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological significance of thyroid dysfunction in patients treated with Ate/Bev has not been comprehensively addressed. We aimed to comprehensively evaluate the clinical and immunological implications of thyroid dysfunction in unresectable HCC patients treated with Ate/Bev. Methods: We enrolled 208 patients with unresectable HCC treated with Ate/Bev from three Korean cancer centers. Thyroid adverse events (AEs) were reviewed, and cytokines and T cells in the blood samples were analyzed at baseline. For external validation, we analyzed clinical outcomes according to thyroid AEs in patients treated with Ate/Bev in the IMbrave150 study. Results: Forty-one (19.7%) out of 208 patients experienced thyroid dysfunction (hypothyroidism [17.3%] and thyrotoxicosis [5.8%]) after Ate/Bev treatment. Median time to onset of hypothyroidism and thyrotoxicosis after Ate/Bev treatment was 3.5 and 1.3 months, respectively. Patients with thyroid AEs demonstrated significantly better progression-free survival, overall survival, and objective response rate than those without thyroid AEs. These findings were still consistent even after adjusting for confounding factors. Furthermore, favorable survival outcomes in patients with thyroid AEs were also validated in a cohort of IMbrave150 patients. While patients with thyrotoxicosis showed a significantly lower level of baseline IL-6, those with hypothyroidism did not show significant differences in circulating cytokine levels and CD8+ T-cell fractions. Conclusions: A fraction of patients with HCC treated with Ate/Bev experienced thyroid dysfunction, and the development of thyroid AEs was associated with favorable clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Author

Song, Young Shin, primary, Yang, Hannah, additional, Kang, Beodeul, additional, Cheon, Jaekyung, additional, Kim, Ilhwan, additional, Kim, Hyeyeong, additional, Lee, Won Suk, additional, Sang, Yun Beom, additional, Jung, Sanghoon, additional, Lim, Ho Yeong, additional, Gaillard, Vincent E., additional, Kim, Chan, additional, and Chon, Hong Jae, additional

Published
2023
Full Text
View/download PDF

19. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake

Author

Lee, Young Ah, Lee, Hyunjung, Im, Sun-Wha, Song, Young Shin, Oh, Do-Youn, Kang, Hyoung Jin, Won, Jae-Kyung, Jung, Kyeong Cheon, Kwon, Dohee, Chung, Eun-Jae, Hah, J. Hun, Paeng, Jin Chul, Kim, Ji-Hoon, Choi, Jaeyong, Kim, Ok-Hee, Oh, Ji Min, Ahn, Byeong-Cheol, Wirth, Lori J., Shin, Choong Ho, Kim, Jong-Il, and Park, Young Joo

Subjects
Cancer in children -- Care and treatment -- Genetic aspects, Thyroid cancer -- Care and treatment -- Genetic aspects, Molecular targeted therapy -- Methods, Pediatric research, Gene fusion -- Research, Health care industry
Abstract

BACKGROUND. Molecular characterization in pediatric papillary thyroid cancer (PTC), distinct from adult PTC, is important for developing molecularly targeted therapies for progressive radioiodine-refractory ([sup.131]I-refractory) PTC. METHODS. PTC samples from 106 pediatric patients (age range: 4.3-19.8 years; n = 84 girls, n = 22 boys) who were admitted to SNUH (January 1983-March 2020) were available for genomic profiling. Previous transcriptomic data from 125 adult PTC samples were used for comparison. RESULTS. We identified genetic drivers in 80 tumors: 31 with fusion oncogenes (RET in 21 patients, ALK in 6 patients, and NTRK1/3 in 4 patients); 47 with point mutations ([BRAF.sup.V600E] in 41 patients, [TERT.sup.C228T] in 2 patients [1 of whom had a coexisting [BRAF.sup.V600E]], and DICER1 variants in 5 patients); and 2 with amplifications. Fusion oncogene PTCs, which are predominantly detected in younger patients, were at a more advanced stage and showed more recurrent or persistent disease compared with [BRAF.sup.V600E] PTCs, which are detected mostly in adolescents. Pediatric fusion PTCs (in patients CONCLUSIONS. In pediatric patients with fusion oncogene PTC who have [sup.131]I-refractory advanced disease, selective fusiondirected therapy may restore radioiodine avidity and lead to a dramatic tumor response, underscoring the importance of molecular testing in pediatric patients with PTC. FUNDING. The Ministry of Science, ICT and Future Planning (NRF-2016R1A2B4012417 and 2019R1A2C2084332); the Korean Ministry of Health and Welfare (H14C1277); the Ministry of Education (2020R1A6A1A03047972); and the SNUH Research Fund (04-2015-0830). TRIAL REGISTRATION. Two patients received fusion-targeted therapy with larotrectinib (NCT02576431; NAVIGATE) or selpercatinib (LOXO-RET-18018)., Introduction Pediatric papillary thyroid cancers (PTCs) have distinct genetic alterations and a higher proportion of gene fusions compared with adult PTCs, in which point mutations predominate (1). Previous methods to [...]

Published
2021
Full Text
View/download PDF

21. Supplementary tables from A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer

Author

Singh, Thoudam Debraj, primary, Song, Jaeyoung, primary, Kim, Jina, primary, Chin, Jungwook, primary, Ji, Hyun Dong, primary, Lee, Jae-Eon, primary, Lee, Sang Bong, primary, Yoon, Heeseok, primary, Yu, Ji Hoon, primary, Kim, Sang Kyoon, primary, Yoon, Ghil Suk, primary, Hwang, Hayoung, primary, Lee, Ho Won, primary, Oh, Ji Min, primary, Lee, Sang-Woo, primary, Lee, Jaetae, primary, Choi, Hueng-Sik, primary, Na, Soon-Young, primary, Choi, Won-Il, primary, Park, Young Joo, primary, Song, Young Shin, primary, Kim, Young A., primary, Lee, In-Kyu, primary, Cho, Sung Jin, primary, and Jeon, Yong Hyun, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures from A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer

Author

Singh, Thoudam Debraj, primary, Song, Jaeyoung, primary, Kim, Jina, primary, Chin, Jungwook, primary, Ji, Hyun Dong, primary, Lee, Jae-Eon, primary, Lee, Sang Bong, primary, Yoon, Heeseok, primary, Yu, Ji Hoon, primary, Kim, Sang Kyoon, primary, Yoon, Ghil Suk, primary, Hwang, Hayoung, primary, Lee, Ho Won, primary, Oh, Ji Min, primary, Lee, Sang-Woo, primary, Lee, Jaetae, primary, Choi, Hueng-Sik, primary, Na, Soon-Young, primary, Choi, Won-Il, primary, Park, Young Joo, primary, Song, Young Shin, primary, Kim, Young A., primary, Lee, In-Kyu, primary, Cho, Sung Jin, primary, and Jeon, Yong Hyun, primary

Published
2023
Full Text
View/download PDF

43. OR28-06 Assessment of Long Term Quality of Life According to Treatment Options in Low Risk Papillary Thyroid Microcarcinoma Patients - Active Surveillance or Immediate Surgery, (A Follow up Interim Analysis of Maestro)

Author

Shin, Soo Myoung, primary, Kong, Sung Hye, primary, Ryu, Junsun, primary, Kim, Min Joo, primary, Cho, Sun Wook, primary, Song, Young Shin, primary, Yi, Ka Hee, primary, Park, Do Joon, primary, Hwangbo, Yul, primary, Lee, You Jin, primary, Lee, Kyu Eun, primary, Kim, Su-jin, primary, Jeong, Woo-Jin, primary, Chung, Eun-Jae, primary, Hah, Jeong Hun, primary, Choi, June Young, primary, Ryu, Chang Hwan, primary, Jung, Yuh-Seog, primary, Lee, Eun Kyung, primary, Park, Young Joo, primary, and Moon, Jae Hoon, primary

Published
2020
Full Text
View/download PDF

45. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer

Author

Singh, Thoudam Debraj, primary, Song, Jaeyoung, additional, Kim, Jina, additional, Chin, Jungwook, additional, Ji, Hyun Dong, additional, Lee, Jae-Eon, additional, Lee, Sang Bong, additional, Yoon, Heeseok, additional, Yu, Ji Hoon, additional, Kim, Sang Kyoon, additional, Yoon, Ghil Suk, additional, Hwang, Hayoung, additional, Lee, Ho Won, additional, Oh, Ji Min, additional, Lee, Sang-Woo, additional, Lee, Jaetae, additional, Choi, Hueng-Sik, additional, Na, Soon-Young, additional, Choi, Won-Il, additional, Park, Young Joo, additional, Song, Young Shin, additional, Kim, Young A., additional, Lee, In-Kyu, additional, Cho, Sung Jin, additional, and Jeon, Yong Hyun, additional

Published
2019
Full Text
View/download PDF

46. Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)

Author

Kong, Sung Hye, primary, Ryu, Junsun, additional, Kim, Min Joo, additional, Cho, Sun Wook, additional, Song, Young Shin, additional, Yi, Ka Hee, additional, Park, Do Joon, additional, Hwangbo, Yul, additional, Lee, You Jin, additional, Lee, Kyu Eun, additional, Kim, Su-jin, additional, Jeong, Woo-Jin, additional, Chung, Eun-Jae, additional, Hah, Jeong Hun, additional, Choi, June Young, additional, Ryu, Chang Hwan, additional, Jung, Yuh-Seog, additional, Moon, Jae Hoon, additional, Lee, Eun Kyung, additional, and Park, Young Joo, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results